Adult cardiac surgery blood/blood product utilization in the post aprotinin era: an 855 patient, community hospital, retrospective experience

被引:0
|
作者
Sharma A.D. [1 ]
Al-Achi A. [2 ]
Behrend D. [1 ]
Seccombe J.F. [1 ]
机构
[1] Department of Cardiac Anesthesia/Cardiac Surgery, St. Vincent Hospital Heart Center, 835 South Van Buren Street, Green Bay, 54307-3508, WI
[2] Pharmaceutical Sciences, Campbell University, Buies Creek, NC
关键词
Bleeding; Coagulation; Transfusion;
D O I
10.1007/s12055-015-0413-2
中图分类号
学科分类号
摘要
Background and objectives: Prior to 2008, when it was withdrawn, aprotinin use in cardiac surgery patients was associated with reduced bleeding and blood utilization, but studies linked its administration to increased patient mortality. We investigated (a) blood/blood product utilization between 2008 and 2013 at our community hospital heart center according to the type of surgery performed following the withdrawal of aprotinin and (b) clinical variables associated with increased patient blood utilization. Materials and methods: Seven hundred nine patients were retrospectively investigated for blood/blood product utilization. Variables examined were patient age, body surface area (BSA), gender, preoperative creatinine level, hematocrit level, total cell saved blood (CSB) administered, cardiopulmonary bypass (CPB) time, type of surgical procedure performed, and preoperative clopidogrel usage. Variables (categorical and continuous) were placed into a forward stepwise regression model for the continuous outcome, packed red blood cell (PRBC) utilization. The stepwise function utilized a P value threshold of 0.25 for entering the model and 0.1 for leaving the model. Results: For coronary artery bypass graft (CABG) surgery, use of PRBC was 29.26 % (0.75/1.44), of platelets was 14.18 % (0.24/0.72), of fresh frozen plasma (FFP) was 7.34 % (0.19/0.78), and of cryoprecipitate was 10.63 % (0.23/0.97) among our patient sample. [Data expressed as percent patient utilization, mean/S.D. in units transfused]. Increased age, smaller BSA, higher preoperative creatinine level, lower preoperative hematocrit level, longer CPB time, and increased CSB administration was associated with increased PRBC administration (P < 0.0001). Conclusion: At our community heart surgery center, with a multidisciplinary blood conservation program in place, expected increase in blood/blood product utilization following aprotinin withdrawal was not experienced. © 2016, Indian Association of Cardiovascular-Thoracic Surgeons.
引用
收藏
页码:87 / 96
页数:9
相关论文
共 27 条
  • [1] Early Postoperative Outcomes and Blood Product Utilization in Adult Cardiac Surgery The Post-Aprotinin Era
    DeSantis, Stacia M.
    Toole, J. Matthew
    Kratz, John M.
    Uber, Walter E.
    Wheat, Margaret J.
    Stroud, Martha R.
    Ikonomidis, John S.
    Spinale, Francis G.
    CIRCULATION, 2011, 124 (11) : S62 - S69
  • [2] Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization
    Strouch, Zaneta Y.
    Drum, Melinda L.
    Chaney, Mark A.
    JOURNAL OF CLINICAL ANESTHESIA, 2009, 21 (07) : 502 - 507
  • [3] Blood utilization in revision versus first-time cardiac surgery: an update in the era of patient blood management
    Hensley, Nadia B.
    Kostibas, Megan P.
    Yang, William W.
    Crawford, Todd C.
    Mandal, Kaushik
    Gupta, Pranjal B.
    Frank, Steven M.
    Brown, Charles H.
    TRANSFUSION, 2018, 58 (01) : 168 - 175
  • [4] Efficacy of aprotinin as a blood conservation technique for adult deformity spinal surgery - A retrospective study
    Tayyab, Neil Arif
    Mariller, Marjorie M.
    Rivlin, Michael
    Berekashvili, Ketevan
    Bitan, Fabien D.
    Casden, Andrew M.
    Kuflik, Paul
    Neuwirth, Michael G.
    SPINE, 2008, 33 (16) : 1775 - 1781
  • [5] Impact of Patient Blood Management on Red Blood Cell Utilization in an Urban Community Teaching Hospital: A Seven-Year Retrospective Study
    Wu, Ding Wen
    Friedman, Mark T.
    Lombardi, Daniel P.
    Hwang, Richard
    Sender, Joel
    Cobaj, Valdet
    Niazi, Masooma
    Li, Yanhua
    Karpinos, Robert
    LIFE-BASEL, 2024, 14 (02):
  • [6] Effect of patient age on blood product transfusion after cardiac surgery
    Ad, Niv
    Massimiano, Paul S.
    Burton, Nelson A.
    Halpin, Linda
    Pritchard, Graciela
    Shuman, Deborah J.
    Holmes, Sari D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 150 (01) : 209 - 214
  • [7] The Results of Cardiac Surgery in Terms of Patient Blood Management in Our Hospital
    Sert, Gokce Selcuk
    Cavus, Mine
    Kemerci, Perihan
    Bektas, Serife
    Demir, Zeliha Asli
    Ozgok, Aysegul
    Sert, Dogan
    Karadeniz, Umit
    TURKISH JOURNAL OF ANAESTHESIOLOGY AND REANIMATION, 2019, 47 (05) : 402 - 406
  • [8] High-dose aprotinin, blood product transfusions, and short-term outcome in neonates and infants: a pediatric cardiac surgery center experience
    Bojan, Mirela
    Boulat, Claire
    Peperstraete, Harlinde
    Pouard, Philippe
    PEDIATRIC ANESTHESIA, 2012, 22 (08) : 818 - 825
  • [9] Dosing, Monitoring, Blood Product Utilization, and Thromboembolic Complications of Four-Factor Prothrombin Complex Concentrate as Part of an Institutional Protocol in Pediatric Cardiac Surgery: A Retrospective Cohort Study
    Kiskaddon, Amy L.
    Goldenberg, Neil A.
    Fierstein, Jamie L.
    Miller, Alexandra
    Quintessenza, James A.
    Kartha, Vyas M.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024, 50 (06) : 873 - 882
  • [10] Intraoperative blood product transfusion in pediatric cardiac surgery patients: A retrospective review of adverse outcomes
    Busack, Christopher
    Rana, Md Sohel
    Beidas, Yousef
    Almirante, Juan Miguel
    Deutsch, Nina
    Matisoff, Andrew
    PEDIATRIC ANESTHESIA, 2023, 33 (05) : 387 - 397